Genitourinary Cancer
APPs Are Key in GU Cancer Care
February 24, 2021
Article
An nurse practitioner discusses how she supports multiple providers in a large academic practice.
Better Treatment Needed for Androgen Receptor Adverse Events
February 23, 2021
Article
While the majority of patients on androgen receptor therapy experienced adverse events, more than a third did not have them resolved.
Vicineum Granted Priority Review for High-Risk, BCG-Unresponsive Bladder Cancer
February 18, 2021
Article
The FDA has accepted and granted a priority review designation to the biologics license application for Vicineum for use in patients with high-risk Bacillus Calmette-Guérin–unresponsive non–muscle invasive bladder cancer.
High TMB, Adverse Events May Predict Immunotherapy Response in mUC
February 17, 2021
Article
Patients with metastatic urothelial carcinoma with higher tumor mutational burden and who experienced immune-related adverse events tended to have higher response rates to immune checkpoint inhibitor.
Metastatic Prostate Cancer Rates Rise as PSA Screening Decreases
February 16, 2021
Article
Reductions in prostate-specific antigen screening are likely responsible for the recent increase in metastatic prostate cancer cases in the United States.
Sapanisertib: Poor Activity, More AEs in mRCC
February 13, 2021
Article
Sapanisertib failed to show significant activity and a favorable toxicity profile in patients with refractory metastatic renal cell carcinoma (mRCC) regardless of mTOR or PTEN status.
Shorter SBRT Treatment Is Safe, Efficacious in High-Risk Prostate Cancer
January 28, 2021
Article
A shorter course of stereotactic body radiotherapy (SBRT) has been shown to have encouraging efficacy with favorable toxicity when used in patients with high-risk prostate cancer in a multi-institutional, international setting, according to findings from a study published in the International Journal of Radiation Oncology, Biology, Physics.
FDA Approves Cabozantinib Plus Nivolumab for Frontline Advanced RCC
January 23, 2021
Article
The FDA approved cabozantinib (Cabometyx) plus nivolumab (Opdivo) for the frontline treatment of patients with advanced renal cell carcinoma (RCC).
Aspirin May Offer Survival Advantage in Breast, Bladder Cancer
January 22, 2021
Article
Findings of an epidemiological study show that regular aspirin use could boost survival in older patients with breast and bladder cancers, but more research is still needed.
Padeliporfin ImPACT Granted Fast Track Status for Upper-Tract Urothelial Cancer
January 19, 2021
Article
The FDA has granted a fast track designation to padeliporfin Immune Photo Activated Cancer Therapy (ImPACT) for use in the treatment of patients with low-grade and unifocal upper-tract urothelial cancer (UTUC), according to an announcement from Steba Biotech.